Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CEW

This article was originally published in The Rose Sheet

Executive Summary

Nine industry execs receive Cosmetic Executive Women Achiever Award Oct. 31. Award, established in 1975, recognizes leading execs who have contributed to beauty industry growth and advancement of women. Recipients include Studio at Fred Segal founder, Creative Director Robin Coe-Hutshing, L'Oréal President/General Manager Carol Hamilton, Makeup Artist Sonia Kashuk, Shiseido U.S. President Heidi Manheimer, Procter & Gamble Global Cosmetics & Marketing VP Anne Martin, Rodan & Fields founders Katie Rodan and Kathy Fields, YSL Beauté Chairman/CEO Chantal Roos and Clinique North America President Eunice Valdivia. Evelyn Lauder, Estee Lauder senior corporate VP, also honored as first recipient of Inner Beauty Award for individual whose contributions go beyond professional and corporate requirements. Lauder accepted award from Sen. Hillary Clinton (D-N.Y.) for founding the Breast Cancer Research Foundation...

You may also be interested in...



Deals Shaping The Medical Industry, February 2020

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.

2020 Could Spell The End Of Mega-Mergers, For Now

Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.

Creating Stability In A Time Of Transition

UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.

UsernamePublicRestriction

Register

RS011648

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel